← Back to Analyst Consensus 
PCVX Buy
Vaxcyte, Inc.
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 5 reiterations from 5 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | — | 50% |
| Oct 5, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Oct 5, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Oct 5, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Sep 28, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Sep 25, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Feb 26, 2026 | BTIG | maintain | Buy → Buy | $89 | 52% |
| Feb 2, 2026 | Guggenheim | reiterate | Buy → Buy | $116 | 52% |
| Nov 10, 2025 | BTIG | reiterate | Buy → Buy | $85 | 52% |
| Oct 16, 2025 | BTIG | maintain | Buy → Buy | $85 | 52% |
| Sep 12, 2025 | Goldman Sachs | initiate | — → Neutral | $38 | 54% |
| Apr 22, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Apr 8, 2025 | Needham | reiterate | Buy → Buy | $90 | 50% |
| Apr 1, 2025 | Goldman Sachs | maintain | Buy → Buy | $100 | 54% |
| Apr 1, 2025 | B of A Securities | maintain | Buy → Buy | $137 | 53% |
| Apr 1, 2025 | Needham | maintain | Buy → Buy | $90 | 50% |
| Mar 12, 2025 | Guggenheim | reiterate | Buy → Buy | $160 | 52% |
| Feb 26, 2025 | Guggenheim | reiterate | Buy → Buy | $160 | 52% |
| Feb 26, 2025 | Needham | reiterate | Buy → Buy | $140 | 50% |
| Feb 24, 2025 | BTIG | reiterate | Buy → Buy | $160 | 52% |
| Feb 11, 2025 | Needham | reiterate | Buy → Buy | $14 | 50% |
| Dec 24, 2024 | BTIG | reiterate | Buy → Buy | $160 | 52% |
| Dec 20, 2024 | Goldman Sachs | initiate | — → Buy | $135 | 54% |
| Nov 6, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Nov 6, 2024 | Needham | reiterate | Buy → Buy | $140 | 50% |
| Sep 10, 2024 | Mizuho | maintain | Outperform → Outperform | $163 | 52% |
| Sep 4, 2024 | B of A Securities | maintain | Buy → Buy | $140 | 53% |
| Sep 3, 2024 | Leerink Partners | maintain | Outperform → Outperform | $153 | 51% |
| Sep 3, 2024 | Jefferies | maintain | Buy → Buy | $129 | 52% |
| Sep 3, 2024 | Needham | maintain | Buy → Buy | $140 | 50% |
| Sep 3, 2024 | BTIG | maintain | Buy → Buy | $160 | 52% |
| Aug 7, 2024 | BTIG | reiterate | Buy → Buy | $98 | 52% |
| Aug 7, 2024 | Needham | reiterate | Buy → Buy | $95 | 50% |
| Jun 28, 2024 | Needham | reiterate | Buy → Buy | $95 | 50% |
| Jun 20, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| May 9, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| May 9, 2024 | Needham | reiterate | Buy → Buy | $95 | 50% |
| Apr 10, 2024 | Needham | reiterate | Buy → Buy | $95 | 50% |
| Mar 12, 2024 | Mizuho | maintain | Buy → Buy | $113 | 52% |
| Feb 28, 2024 | Needham | maintain | Buy → Buy | $95 | 50% |
| Jan 2, 2024 | B of A Securities | maintain | Buy → Buy | $80 | 53% |
| Dec 7, 2023 | Mizuho | initiate | — → Buy | $69 | 52% |
| Nov 7, 2023 | Needham | reiterate | Buy → Buy | $58 | 50% |
| Aug 22, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $70 | 50% |
| Aug 9, 2023 | Needham | reiterate | Buy → Buy | $58 | 50% |
| May 9, 2023 | Needham | reiterate | — → Buy | $58 | 50% |
| Apr 18, 2023 | TD Cowen | initiate | — → Outperform | $0 | 54% |
| Apr 18, 2023 | B of A Securities | maintain | — → Buy | $68 | 53% |
| Mar 1, 2023 | Cantor Fitzgerald | maintain | Overweight → Overweight | $70 | 50% |
| Feb 28, 2023 | Guggenheim | maintain | — → Buy | $65 | 52% |
Price Target Trend
Jun 23, 2026 Latest: $117.3 Oct 25, 2026
EPS Estimates
+1y $-7.12
Lo: $-11.42 Hi: $-4.96
7 analysts ▲1
+1q $-1.96
Lo: $-2.69 Hi: $-0.86
7 analysts ▲1
0y $-8.14
Lo: $-9.66 Hi: $-6.19
7 analysts 0q $-2.11
Lo: $-2.68 Hi: $-1.67
7 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days